Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Precision BioSciences has filed two patent infringement lawsuits against Cellectis and a number of its affiliates in the US District Court for the Eastern District of North Carolina.
Subscribe to our email newsletter
The lawsuit requests monetary damages and permanent injunction against importation of infringing materials into the US.
Precision claims that Cellectis’ manufacture, use, sale, and importation of certain engineered meganucleases infringe US Patent Nos. 8,119,381 and 8,119,361 related to its directed nuclease editor genome engineering technology.
Precision BioSciences previously announced in October 2011 that it had filed suit against Cellectis for alleged infringement of US Patent No. 8,021,867.
Precision CEO Matthew Kane said they will not tolerate the unauthorized and wrongful use and importation of their inventions and materials.